Office-Based, Point-of-Care, Low-Field MRI System to Guide Prostate Interventions: Recent Developments

Abstract Prostate cancer (PCa) is the second most frequently diagnosed cancer in males; early-stage PCa is asymptomatic, and PCa has an indolent course. The current standard of care of systematic transrectal biopsy (SBx) is preferred by urologists because of its ease of use and portability, despite its shortcomings in cancer detection rate. The advent of multi-parametric MRI (mpMRI)-enabled PIRADS protocol for lesion diagnosis and characterisation has helped minimise unnecessary biopsies, supporting the active surveillance protocol of patients with low-risk PCa. The use of annotated pre-procedure MRI fused with real-time ultrasound (US) to guide biopsies has been gaining traction in clinical use, but the challenges in registration of two different modalities, gland deformation due to the probe, and significant learning curve associated with fusion have resulted in slower than expected adoption in routine clinical practice. Moreover, the fusion biopsy has only marginally improved cancer detection rate, with a complex workflow. Higher infection rate with transrectal prostate interventions has resulted in an increased use of the transperineal approach to guide biopsies and therapies. There has been significant progress made in the development of point-of-care, portable MRI systems for specific use. In this report, the authors discuss the recent developments in office-based prostate interventions that have occurred with the arrival of low-field MRI systems. The smaller footprint of the low-field system avoids the high costs associated with the installation and management of regular MRI. Additionally, the availability of transperineal MRI visible grid makes the targeting and guidance processes relatively easier with a less-steep learning curve. Since the system uses pre-plan high-field MRI acquired in the same transverse orientation as the low-field MRI, registration errors are smaller than the MRI–US registration. The use of MRI to target lesions has reduced the number of cores sampled, benefiting the patient with early clinical study showing significantly higher cancer detection rate than SBx. Ausführliche Beschreibung

Gespeichert in:

Autor*in:	Jordan Nasri [verfasserIn] Vinayak G. Wagaskar [verfasserIn] Sneha Parekha [verfasserIn] John D. Adams, Jr [verfasserIn] Dinesh Kumar [verfasserIn] Srirama S. Venkataraman [verfasserIn] Ashutosh K. Tewari [verfasserIn]

Format:	E-Artikel
Sprache:	Englisch

Erschienen:	2021

Schlagwörter:	low-field mri multi-parametric mri (mpmri) portable mri prostate cancer (pca) systematic transrectal biopsy (sbx)

Übergeordnetes Werk:	In: European Medical Journal Urology - European Medical Journal, 2015, 9(2021), 1, Seite 83-90
Übergeordnetes Werk:	volume:9 ; year:2021 ; number:1 ; pages:83-90

Links:	Link aufrufen Link aufrufen Journal toc

Katalog-ID:	DOAJ057352275

Internformat


LEADER	01000caa a22002652 4500
001	DOAJ057352275
003	DE-627
005	20230308211421.0
007	cr uuu---uuuuu
008	230227s2021 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)DOAJ057352275
035			\|a (DE-599)DOAJ0a209954e0004e55a810d1ab4bfb9ae5
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
050		0	\|a RC870-923
100	0		\|a Jordan Nasri \|e verfasserin \|4 aut
245	1	0	\|a Office-Based, Point-of-Care, Low-Field MRI System to Guide Prostate Interventions: Recent Developments
264		1	\|c 2021
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
520			\|a Abstract Prostate cancer (PCa) is the second most frequently diagnosed cancer in males; early-stage PCa is asymptomatic, and PCa has an indolent course. The current standard of care of systematic transrectal biopsy (SBx) is preferred by urologists because of its ease of use and portability, despite its shortcomings in cancer detection rate. The advent of multi-parametric MRI (mpMRI)-enabled PIRADS protocol for lesion diagnosis and characterisation has helped minimise unnecessary biopsies, supporting the active surveillance protocol of patients with low-risk PCa. The use of annotated pre-procedure MRI fused with real-time ultrasound (US) to guide biopsies has been gaining traction in clinical use, but the challenges in registration of two different modalities, gland deformation due to the probe, and significant learning curve associated with fusion have resulted in slower than expected adoption in routine clinical practice. Moreover, the fusion biopsy has only marginally improved cancer detection rate, with a complex workflow. Higher infection rate with transrectal prostate interventions has resulted in an increased use of the transperineal approach to guide biopsies and therapies. There has been significant progress made in the development of point-of-care, portable MRI systems for specific use. In this report, the authors discuss the recent developments in office-based prostate interventions that have occurred with the arrival of low-field MRI systems. The smaller footprint of the low-field system avoids the high costs associated with the installation and management of regular MRI. Additionally, the availability of transperineal MRI visible grid makes the targeting and guidance processes relatively easier with a less-steep learning curve. Since the system uses pre-plan high-field MRI acquired in the same transverse orientation as the low-field MRI, registration errors are smaller than the MRI–US registration. The use of MRI to target lesions has reduced the number of cores sampled, benefiting the patient with early clinical study showing significantly higher cancer detection rate than SBx.
650		4	\|a low-field mri
650		4	\|a multi-parametric mri (mpmri)
650		4	\|a portable mri
650		4	\|a prostate cancer (pca)
650		4	\|a systematic transrectal biopsy (sbx)
653		0	\|a Diseases of the genitourinary system. Urology
700	0		\|a Vinayak G. Wagaskar \|e verfasserin \|4 aut
700	0		\|a Sneha Parekha \|e verfasserin \|4 aut
700	0		\|a John D. Adams, Jr \|e verfasserin \|4 aut
700	0		\|a Dinesh Kumar \|e verfasserin \|4 aut
700	0		\|a Srirama S. Venkataraman \|e verfasserin \|4 aut
700	0		\|a Ashutosh K. Tewari \|e verfasserin \|4 aut
773	0	8	\|i In \|t European Medical Journal Urology \|d European Medical Journal, 2015 \|g 9(2021), 1, Seite 83-90 \|w (DE-627)1747627801 \|x 20534213 \|7 nnns
773	1	8	\|g volume:9 \|g year:2021 \|g number:1 \|g pages:83-90
856	4	0	\|u https://doaj.org/article/0a209954e0004e55a810d1ab4bfb9ae5 \|z kostenfrei
856	4	0	\|u https://www.emjreviews.com/urology/article/office-based-point-of-care-low-field-mri-system-to-guide-prostate-interventions-recent-developments-j180121/ \|z kostenfrei
856	4	2	\|u https://doaj.org/toc/2053-4213 \|y Journal toc \|z kostenfrei
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_DOAJ
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_95
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_151
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_602
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4700
951			\|a AR
952			\|d 9 \|j 2021 \|e 1 \|h 83-90

Indexfelder

author_variant	j n jn v g w vgw s p sp d a j j daj dajj d k dk s s v ssv a k t akt
matchkey_str	article:20534213:2021----::fieaepitfaeofedrssetgiersaenevn
hierarchy_sort_str	2021
callnumber-subject-code	RC
publishDate	2021
allfields	(DE-627)DOAJ057352275 (DE-599)DOAJ0a209954e0004e55a810d1ab4bfb9ae5 DE-627 ger DE-627 rakwb eng RC870-923 Jordan Nasri verfasserin aut Office-Based, Point-of-Care, Low-Field MRI System to Guide Prostate Interventions: Recent Developments 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Prostate cancer (PCa) is the second most frequently diagnosed cancer in males; early-stage PCa is asymptomatic, and PCa has an indolent course. The current standard of care of systematic transrectal biopsy (SBx) is preferred by urologists because of its ease of use and portability, despite its shortcomings in cancer detection rate. The advent of multi-parametric MRI (mpMRI)-enabled PIRADS protocol for lesion diagnosis and characterisation has helped minimise unnecessary biopsies, supporting the active surveillance protocol of patients with low-risk PCa. The use of annotated pre-procedure MRI fused with real-time ultrasound (US) to guide biopsies has been gaining traction in clinical use, but the challenges in registration of two different modalities, gland deformation due to the probe, and significant learning curve associated with fusion have resulted in slower than expected adoption in routine clinical practice. Moreover, the fusion biopsy has only marginally improved cancer detection rate, with a complex workflow. Higher infection rate with transrectal prostate interventions has resulted in an increased use of the transperineal approach to guide biopsies and therapies. There has been significant progress made in the development of point-of-care, portable MRI systems for specific use. In this report, the authors discuss the recent developments in office-based prostate interventions that have occurred with the arrival of low-field MRI systems. The smaller footprint of the low-field system avoids the high costs associated with the installation and management of regular MRI. Additionally, the availability of transperineal MRI visible grid makes the targeting and guidance processes relatively easier with a less-steep learning curve. Since the system uses pre-plan high-field MRI acquired in the same transverse orientation as the low-field MRI, registration errors are smaller than the MRI–US registration. The use of MRI to target lesions has reduced the number of cores sampled, benefiting the patient with early clinical study showing significantly higher cancer detection rate than SBx. low-field mri multi-parametric mri (mpmri) portable mri prostate cancer (pca) systematic transrectal biopsy (sbx) Diseases of the genitourinary system. Urology Vinayak G. Wagaskar verfasserin aut Sneha Parekha verfasserin aut John D. Adams, Jr verfasserin aut Dinesh Kumar verfasserin aut Srirama S. Venkataraman verfasserin aut Ashutosh K. Tewari verfasserin aut In European Medical Journal Urology European Medical Journal, 2015 9(2021), 1, Seite 83-90 (DE-627)1747627801 20534213 nnns volume:9 year:2021 number:1 pages:83-90 https://doaj.org/article/0a209954e0004e55a810d1ab4bfb9ae5 kostenfrei https://www.emjreviews.com/urology/article/office-based-point-of-care-low-field-mri-system-to-guide-prostate-interventions-recent-developments-j180121/ kostenfrei https://doaj.org/toc/2053-4213 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2021 1 83-90
spelling	(DE-627)DOAJ057352275 (DE-599)DOAJ0a209954e0004e55a810d1ab4bfb9ae5 DE-627 ger DE-627 rakwb eng RC870-923 Jordan Nasri verfasserin aut Office-Based, Point-of-Care, Low-Field MRI System to Guide Prostate Interventions: Recent Developments 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Prostate cancer (PCa) is the second most frequently diagnosed cancer in males; early-stage PCa is asymptomatic, and PCa has an indolent course. The current standard of care of systematic transrectal biopsy (SBx) is preferred by urologists because of its ease of use and portability, despite its shortcomings in cancer detection rate. The advent of multi-parametric MRI (mpMRI)-enabled PIRADS protocol for lesion diagnosis and characterisation has helped minimise unnecessary biopsies, supporting the active surveillance protocol of patients with low-risk PCa. The use of annotated pre-procedure MRI fused with real-time ultrasound (US) to guide biopsies has been gaining traction in clinical use, but the challenges in registration of two different modalities, gland deformation due to the probe, and significant learning curve associated with fusion have resulted in slower than expected adoption in routine clinical practice. Moreover, the fusion biopsy has only marginally improved cancer detection rate, with a complex workflow. Higher infection rate with transrectal prostate interventions has resulted in an increased use of the transperineal approach to guide biopsies and therapies. There has been significant progress made in the development of point-of-care, portable MRI systems for specific use. In this report, the authors discuss the recent developments in office-based prostate interventions that have occurred with the arrival of low-field MRI systems. The smaller footprint of the low-field system avoids the high costs associated with the installation and management of regular MRI. Additionally, the availability of transperineal MRI visible grid makes the targeting and guidance processes relatively easier with a less-steep learning curve. Since the system uses pre-plan high-field MRI acquired in the same transverse orientation as the low-field MRI, registration errors are smaller than the MRI–US registration. The use of MRI to target lesions has reduced the number of cores sampled, benefiting the patient with early clinical study showing significantly higher cancer detection rate than SBx. low-field mri multi-parametric mri (mpmri) portable mri prostate cancer (pca) systematic transrectal biopsy (sbx) Diseases of the genitourinary system. Urology Vinayak G. Wagaskar verfasserin aut Sneha Parekha verfasserin aut John D. Adams, Jr verfasserin aut Dinesh Kumar verfasserin aut Srirama S. Venkataraman verfasserin aut Ashutosh K. Tewari verfasserin aut In European Medical Journal Urology European Medical Journal, 2015 9(2021), 1, Seite 83-90 (DE-627)1747627801 20534213 nnns volume:9 year:2021 number:1 pages:83-90 https://doaj.org/article/0a209954e0004e55a810d1ab4bfb9ae5 kostenfrei https://www.emjreviews.com/urology/article/office-based-point-of-care-low-field-mri-system-to-guide-prostate-interventions-recent-developments-j180121/ kostenfrei https://doaj.org/toc/2053-4213 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2021 1 83-90
allfields_unstemmed	(DE-627)DOAJ057352275 (DE-599)DOAJ0a209954e0004e55a810d1ab4bfb9ae5 DE-627 ger DE-627 rakwb eng RC870-923 Jordan Nasri verfasserin aut Office-Based, Point-of-Care, Low-Field MRI System to Guide Prostate Interventions: Recent Developments 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Prostate cancer (PCa) is the second most frequently diagnosed cancer in males; early-stage PCa is asymptomatic, and PCa has an indolent course. The current standard of care of systematic transrectal biopsy (SBx) is preferred by urologists because of its ease of use and portability, despite its shortcomings in cancer detection rate. The advent of multi-parametric MRI (mpMRI)-enabled PIRADS protocol for lesion diagnosis and characterisation has helped minimise unnecessary biopsies, supporting the active surveillance protocol of patients with low-risk PCa. The use of annotated pre-procedure MRI fused with real-time ultrasound (US) to guide biopsies has been gaining traction in clinical use, but the challenges in registration of two different modalities, gland deformation due to the probe, and significant learning curve associated with fusion have resulted in slower than expected adoption in routine clinical practice. Moreover, the fusion biopsy has only marginally improved cancer detection rate, with a complex workflow. Higher infection rate with transrectal prostate interventions has resulted in an increased use of the transperineal approach to guide biopsies and therapies. There has been significant progress made in the development of point-of-care, portable MRI systems for specific use. In this report, the authors discuss the recent developments in office-based prostate interventions that have occurred with the arrival of low-field MRI systems. The smaller footprint of the low-field system avoids the high costs associated with the installation and management of regular MRI. Additionally, the availability of transperineal MRI visible grid makes the targeting and guidance processes relatively easier with a less-steep learning curve. Since the system uses pre-plan high-field MRI acquired in the same transverse orientation as the low-field MRI, registration errors are smaller than the MRI–US registration. The use of MRI to target lesions has reduced the number of cores sampled, benefiting the patient with early clinical study showing significantly higher cancer detection rate than SBx. low-field mri multi-parametric mri (mpmri) portable mri prostate cancer (pca) systematic transrectal biopsy (sbx) Diseases of the genitourinary system. Urology Vinayak G. Wagaskar verfasserin aut Sneha Parekha verfasserin aut John D. Adams, Jr verfasserin aut Dinesh Kumar verfasserin aut Srirama S. Venkataraman verfasserin aut Ashutosh K. Tewari verfasserin aut In European Medical Journal Urology European Medical Journal, 2015 9(2021), 1, Seite 83-90 (DE-627)1747627801 20534213 nnns volume:9 year:2021 number:1 pages:83-90 https://doaj.org/article/0a209954e0004e55a810d1ab4bfb9ae5 kostenfrei https://www.emjreviews.com/urology/article/office-based-point-of-care-low-field-mri-system-to-guide-prostate-interventions-recent-developments-j180121/ kostenfrei https://doaj.org/toc/2053-4213 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2021 1 83-90
allfieldsGer	(DE-627)DOAJ057352275 (DE-599)DOAJ0a209954e0004e55a810d1ab4bfb9ae5 DE-627 ger DE-627 rakwb eng RC870-923 Jordan Nasri verfasserin aut Office-Based, Point-of-Care, Low-Field MRI System to Guide Prostate Interventions: Recent Developments 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Prostate cancer (PCa) is the second most frequently diagnosed cancer in males; early-stage PCa is asymptomatic, and PCa has an indolent course. The current standard of care of systematic transrectal biopsy (SBx) is preferred by urologists because of its ease of use and portability, despite its shortcomings in cancer detection rate. The advent of multi-parametric MRI (mpMRI)-enabled PIRADS protocol for lesion diagnosis and characterisation has helped minimise unnecessary biopsies, supporting the active surveillance protocol of patients with low-risk PCa. The use of annotated pre-procedure MRI fused with real-time ultrasound (US) to guide biopsies has been gaining traction in clinical use, but the challenges in registration of two different modalities, gland deformation due to the probe, and significant learning curve associated with fusion have resulted in slower than expected adoption in routine clinical practice. Moreover, the fusion biopsy has only marginally improved cancer detection rate, with a complex workflow. Higher infection rate with transrectal prostate interventions has resulted in an increased use of the transperineal approach to guide biopsies and therapies. There has been significant progress made in the development of point-of-care, portable MRI systems for specific use. In this report, the authors discuss the recent developments in office-based prostate interventions that have occurred with the arrival of low-field MRI systems. The smaller footprint of the low-field system avoids the high costs associated with the installation and management of regular MRI. Additionally, the availability of transperineal MRI visible grid makes the targeting and guidance processes relatively easier with a less-steep learning curve. Since the system uses pre-plan high-field MRI acquired in the same transverse orientation as the low-field MRI, registration errors are smaller than the MRI–US registration. The use of MRI to target lesions has reduced the number of cores sampled, benefiting the patient with early clinical study showing significantly higher cancer detection rate than SBx. low-field mri multi-parametric mri (mpmri) portable mri prostate cancer (pca) systematic transrectal biopsy (sbx) Diseases of the genitourinary system. Urology Vinayak G. Wagaskar verfasserin aut Sneha Parekha verfasserin aut John D. Adams, Jr verfasserin aut Dinesh Kumar verfasserin aut Srirama S. Venkataraman verfasserin aut Ashutosh K. Tewari verfasserin aut In European Medical Journal Urology European Medical Journal, 2015 9(2021), 1, Seite 83-90 (DE-627)1747627801 20534213 nnns volume:9 year:2021 number:1 pages:83-90 https://doaj.org/article/0a209954e0004e55a810d1ab4bfb9ae5 kostenfrei https://www.emjreviews.com/urology/article/office-based-point-of-care-low-field-mri-system-to-guide-prostate-interventions-recent-developments-j180121/ kostenfrei https://doaj.org/toc/2053-4213 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2021 1 83-90
allfieldsSound	(DE-627)DOAJ057352275 (DE-599)DOAJ0a209954e0004e55a810d1ab4bfb9ae5 DE-627 ger DE-627 rakwb eng RC870-923 Jordan Nasri verfasserin aut Office-Based, Point-of-Care, Low-Field MRI System to Guide Prostate Interventions: Recent Developments 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Abstract Prostate cancer (PCa) is the second most frequently diagnosed cancer in males; early-stage PCa is asymptomatic, and PCa has an indolent course. The current standard of care of systematic transrectal biopsy (SBx) is preferred by urologists because of its ease of use and portability, despite its shortcomings in cancer detection rate. The advent of multi-parametric MRI (mpMRI)-enabled PIRADS protocol for lesion diagnosis and characterisation has helped minimise unnecessary biopsies, supporting the active surveillance protocol of patients with low-risk PCa. The use of annotated pre-procedure MRI fused with real-time ultrasound (US) to guide biopsies has been gaining traction in clinical use, but the challenges in registration of two different modalities, gland deformation due to the probe, and significant learning curve associated with fusion have resulted in slower than expected adoption in routine clinical practice. Moreover, the fusion biopsy has only marginally improved cancer detection rate, with a complex workflow. Higher infection rate with transrectal prostate interventions has resulted in an increased use of the transperineal approach to guide biopsies and therapies. There has been significant progress made in the development of point-of-care, portable MRI systems for specific use. In this report, the authors discuss the recent developments in office-based prostate interventions that have occurred with the arrival of low-field MRI systems. The smaller footprint of the low-field system avoids the high costs associated with the installation and management of regular MRI. Additionally, the availability of transperineal MRI visible grid makes the targeting and guidance processes relatively easier with a less-steep learning curve. Since the system uses pre-plan high-field MRI acquired in the same transverse orientation as the low-field MRI, registration errors are smaller than the MRI–US registration. The use of MRI to target lesions has reduced the number of cores sampled, benefiting the patient with early clinical study showing significantly higher cancer detection rate than SBx. low-field mri multi-parametric mri (mpmri) portable mri prostate cancer (pca) systematic transrectal biopsy (sbx) Diseases of the genitourinary system. Urology Vinayak G. Wagaskar verfasserin aut Sneha Parekha verfasserin aut John D. Adams, Jr verfasserin aut Dinesh Kumar verfasserin aut Srirama S. Venkataraman verfasserin aut Ashutosh K. Tewari verfasserin aut In European Medical Journal Urology European Medical Journal, 2015 9(2021), 1, Seite 83-90 (DE-627)1747627801 20534213 nnns volume:9 year:2021 number:1 pages:83-90 https://doaj.org/article/0a209954e0004e55a810d1ab4bfb9ae5 kostenfrei https://www.emjreviews.com/urology/article/office-based-point-of-care-low-field-mri-system-to-guide-prostate-interventions-recent-developments-j180121/ kostenfrei https://doaj.org/toc/2053-4213 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 9 2021 1 83-90
language	English
source	In European Medical Journal Urology 9(2021), 1, Seite 83-90 volume:9 year:2021 number:1 pages:83-90
sourceStr	In European Medical Journal Urology 9(2021), 1, Seite 83-90 volume:9 year:2021 number:1 pages:83-90
format_phy_str_mv	Article
institution	findex.gbv.de
topic_facet	low-field mri multi-parametric mri (mpmri) portable mri prostate cancer (pca) systematic transrectal biopsy (sbx) Diseases of the genitourinary system. Urology
isfreeaccess_bool	true
container_title	European Medical Journal Urology
authorswithroles_txt_mv	Jordan Nasri @@aut@@ Vinayak G. Wagaskar @@aut@@ Sneha Parekha @@aut@@ John D. Adams, Jr @@aut@@ Dinesh Kumar @@aut@@ Srirama S. Venkataraman @@aut@@ Ashutosh K. Tewari @@aut@@
publishDateDaySort_date	2021-01-01T00:00:00Z
hierarchy_top_id	1747627801
id	DOAJ057352275
language_de	englisch
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ057352275</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308211421.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ057352275</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ0a209954e0004e55a810d1ab4bfb9ae5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC870-923</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Jordan Nasri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Office-Based, Point-of-Care, Low-Field MRI System to Guide Prostate Interventions: Recent Developments</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Prostate cancer (PCa) is the second most frequently diagnosed cancer in males; early-stage PCa is asymptomatic, and PCa has an indolent course. The current standard of care of systematic transrectal biopsy (SBx) is preferred by urologists because of its ease of use and portability, despite its shortcomings in cancer detection rate. The advent of multi-parametric MRI (mpMRI)-enabled PIRADS protocol for lesion diagnosis and characterisation has helped minimise unnecessary biopsies, supporting the active surveillance protocol of patients with low-risk PCa. The use of annotated pre-procedure MRI fused with real-time ultrasound (US) to guide biopsies has been gaining traction in clinical use, but the challenges in registration of two different modalities, gland deformation due to the probe, and significant learning curve associated with fusion have resulted in slower than expected adoption in routine clinical practice. Moreover, the fusion biopsy has only marginally improved cancer detection rate, with a complex workflow. Higher infection rate with transrectal prostate interventions has resulted in an increased use of the transperineal approach to guide biopsies and therapies. There has been significant progress made in the development of point-of-care, portable MRI systems for specific use. In this report, the authors discuss the recent developments in office-based prostate interventions that have occurred with the arrival of low-field MRI systems. The smaller footprint of the low-field system avoids the high costs associated with the installation and management of regular MRI. Additionally, the availability of transperineal MRI visible grid makes the targeting and guidance processes relatively easier with a less-steep learning curve. Since the system uses pre-plan high-field MRI acquired in the same transverse orientation as the low-field MRI, registration errors are smaller than the MRI–US registration. The use of MRI to target lesions has reduced the number of cores sampled, benefiting the patient with early clinical study showing significantly higher cancer detection rate than SBx.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">low-field mri</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">multi-parametric mri (mpmri)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">portable mri</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prostate cancer (pca)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">systematic transrectal biopsy (sbx)</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the genitourinary system. Urology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vinayak G. Wagaskar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sneha Parekha</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">John D. Adams, Jr</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dinesh Kumar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Srirama S. Venkataraman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ashutosh K. Tewari</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">European Medical Journal Urology</subfield><subfield code="d">European Medical Journal, 2015</subfield><subfield code="g">9(2021), 1, Seite 83-90</subfield><subfield code="w">(DE-627)1747627801</subfield><subfield code="x">20534213</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:83-90</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/0a209954e0004e55a810d1ab4bfb9ae5</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.emjreviews.com/urology/article/office-based-point-of-care-low-field-mri-system-to-guide-prostate-interventions-recent-developments-j180121/</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2053-4213</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">2021</subfield><subfield code="e">1</subfield><subfield code="h">83-90</subfield></datafield></record></collection>
callnumber-first	R - Medicine
author	Jordan Nasri
spellingShingle	Jordan Nasri misc RC870-923 misc low-field mri misc multi-parametric mri (mpmri) misc portable mri misc prostate cancer (pca) misc systematic transrectal biopsy (sbx) misc Diseases of the genitourinary system. Urology Office-Based, Point-of-Care, Low-Field MRI System to Guide Prostate Interventions: Recent Developments
authorStr	Jordan Nasri
ppnlink_with_tag_str_mv	@@773@@(DE-627)1747627801
format	electronic Article
delete_txt_mv	keep
author_role	aut aut aut aut aut aut aut
collection	DOAJ
remote_str	true
callnumber-label	RC870-923
illustrated	Not Illustrated
issn	20534213
topic_title	RC870-923 Office-Based, Point-of-Care, Low-Field MRI System to Guide Prostate Interventions: Recent Developments low-field mri multi-parametric mri (mpmri) portable mri prostate cancer (pca) systematic transrectal biopsy (sbx)
topic	misc RC870-923 misc low-field mri misc multi-parametric mri (mpmri) misc portable mri misc prostate cancer (pca) misc systematic transrectal biopsy (sbx) misc Diseases of the genitourinary system. Urology
topic_unstemmed	misc RC870-923 misc low-field mri misc multi-parametric mri (mpmri) misc portable mri misc prostate cancer (pca) misc systematic transrectal biopsy (sbx) misc Diseases of the genitourinary system. Urology
topic_browse	misc RC870-923 misc low-field mri misc multi-parametric mri (mpmri) misc portable mri misc prostate cancer (pca) misc systematic transrectal biopsy (sbx) misc Diseases of the genitourinary system. Urology
format_facet	Elektronische Aufsätze Aufsätze Elektronische Ressource
format_main_str_mv	Text Zeitschrift/Artikel
carriertype_str_mv	cr
hierarchy_parent_title	European Medical Journal Urology
hierarchy_parent_id	1747627801
hierarchy_top_title	European Medical Journal Urology
isfreeaccess_txt	true
familylinks_str_mv	(DE-627)1747627801
title	Office-Based, Point-of-Care, Low-Field MRI System to Guide Prostate Interventions: Recent Developments
ctrlnum	(DE-627)DOAJ057352275 (DE-599)DOAJ0a209954e0004e55a810d1ab4bfb9ae5
title_full	Office-Based, Point-of-Care, Low-Field MRI System to Guide Prostate Interventions: Recent Developments
author_sort	Jordan Nasri
journal	European Medical Journal Urology
journalStr	European Medical Journal Urology
callnumber-first-code	R
lang_code	eng
isOA_bool	true
recordtype	marc
publishDateSort	2021
contenttype_str_mv	txt
container_start_page	83
author_browse	Jordan Nasri Vinayak G. Wagaskar Sneha Parekha John D. Adams, Jr Dinesh Kumar Srirama S. Venkataraman Ashutosh K. Tewari
container_volume	9
class	RC870-923
format_se	Elektronische Aufsätze
author-letter	Jordan Nasri
author2-role	verfasserin
title_sort	office-based, point-of-care, low-field mri system to guide prostate interventions: recent developments
callnumber	RC870-923
title_auth	Office-Based, Point-of-Care, Low-Field MRI System to Guide Prostate Interventions: Recent Developments
abstract	Abstract Prostate cancer (PCa) is the second most frequently diagnosed cancer in males; early-stage PCa is asymptomatic, and PCa has an indolent course. The current standard of care of systematic transrectal biopsy (SBx) is preferred by urologists because of its ease of use and portability, despite its shortcomings in cancer detection rate. The advent of multi-parametric MRI (mpMRI)-enabled PIRADS protocol for lesion diagnosis and characterisation has helped minimise unnecessary biopsies, supporting the active surveillance protocol of patients with low-risk PCa. The use of annotated pre-procedure MRI fused with real-time ultrasound (US) to guide biopsies has been gaining traction in clinical use, but the challenges in registration of two different modalities, gland deformation due to the probe, and significant learning curve associated with fusion have resulted in slower than expected adoption in routine clinical practice. Moreover, the fusion biopsy has only marginally improved cancer detection rate, with a complex workflow. Higher infection rate with transrectal prostate interventions has resulted in an increased use of the transperineal approach to guide biopsies and therapies. There has been significant progress made in the development of point-of-care, portable MRI systems for specific use. In this report, the authors discuss the recent developments in office-based prostate interventions that have occurred with the arrival of low-field MRI systems. The smaller footprint of the low-field system avoids the high costs associated with the installation and management of regular MRI. Additionally, the availability of transperineal MRI visible grid makes the targeting and guidance processes relatively easier with a less-steep learning curve. Since the system uses pre-plan high-field MRI acquired in the same transverse orientation as the low-field MRI, registration errors are smaller than the MRI–US registration. The use of MRI to target lesions has reduced the number of cores sampled, benefiting the patient with early clinical study showing significantly higher cancer detection rate than SBx.
abstractGer	Abstract Prostate cancer (PCa) is the second most frequently diagnosed cancer in males; early-stage PCa is asymptomatic, and PCa has an indolent course. The current standard of care of systematic transrectal biopsy (SBx) is preferred by urologists because of its ease of use and portability, despite its shortcomings in cancer detection rate. The advent of multi-parametric MRI (mpMRI)-enabled PIRADS protocol for lesion diagnosis and characterisation has helped minimise unnecessary biopsies, supporting the active surveillance protocol of patients with low-risk PCa. The use of annotated pre-procedure MRI fused with real-time ultrasound (US) to guide biopsies has been gaining traction in clinical use, but the challenges in registration of two different modalities, gland deformation due to the probe, and significant learning curve associated with fusion have resulted in slower than expected adoption in routine clinical practice. Moreover, the fusion biopsy has only marginally improved cancer detection rate, with a complex workflow. Higher infection rate with transrectal prostate interventions has resulted in an increased use of the transperineal approach to guide biopsies and therapies. There has been significant progress made in the development of point-of-care, portable MRI systems for specific use. In this report, the authors discuss the recent developments in office-based prostate interventions that have occurred with the arrival of low-field MRI systems. The smaller footprint of the low-field system avoids the high costs associated with the installation and management of regular MRI. Additionally, the availability of transperineal MRI visible grid makes the targeting and guidance processes relatively easier with a less-steep learning curve. Since the system uses pre-plan high-field MRI acquired in the same transverse orientation as the low-field MRI, registration errors are smaller than the MRI–US registration. The use of MRI to target lesions has reduced the number of cores sampled, benefiting the patient with early clinical study showing significantly higher cancer detection rate than SBx.
abstract_unstemmed	Abstract Prostate cancer (PCa) is the second most frequently diagnosed cancer in males; early-stage PCa is asymptomatic, and PCa has an indolent course. The current standard of care of systematic transrectal biopsy (SBx) is preferred by urologists because of its ease of use and portability, despite its shortcomings in cancer detection rate. The advent of multi-parametric MRI (mpMRI)-enabled PIRADS protocol for lesion diagnosis and characterisation has helped minimise unnecessary biopsies, supporting the active surveillance protocol of patients with low-risk PCa. The use of annotated pre-procedure MRI fused with real-time ultrasound (US) to guide biopsies has been gaining traction in clinical use, but the challenges in registration of two different modalities, gland deformation due to the probe, and significant learning curve associated with fusion have resulted in slower than expected adoption in routine clinical practice. Moreover, the fusion biopsy has only marginally improved cancer detection rate, with a complex workflow. Higher infection rate with transrectal prostate interventions has resulted in an increased use of the transperineal approach to guide biopsies and therapies. There has been significant progress made in the development of point-of-care, portable MRI systems for specific use. In this report, the authors discuss the recent developments in office-based prostate interventions that have occurred with the arrival of low-field MRI systems. The smaller footprint of the low-field system avoids the high costs associated with the installation and management of regular MRI. Additionally, the availability of transperineal MRI visible grid makes the targeting and guidance processes relatively easier with a less-steep learning curve. Since the system uses pre-plan high-field MRI acquired in the same transverse orientation as the low-field MRI, registration errors are smaller than the MRI–US registration. The use of MRI to target lesions has reduced the number of cores sampled, benefiting the patient with early clinical study showing significantly higher cancer detection rate than SBx.
collection_details	GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700
container_issue	1
title_short	Office-Based, Point-of-Care, Low-Field MRI System to Guide Prostate Interventions: Recent Developments
url	https://doaj.org/article/0a209954e0004e55a810d1ab4bfb9ae5 https://www.emjreviews.com/urology/article/office-based-point-of-care-low-field-mri-system-to-guide-prostate-interventions-recent-developments-j180121/ https://doaj.org/toc/2053-4213
remote_bool	true
author2	Vinayak G. Wagaskar Sneha Parekha John D. Adams, Jr Dinesh Kumar Srirama S. Venkataraman Ashutosh K. Tewari
author2Str	Vinayak G. Wagaskar Sneha Parekha John D. Adams, Jr Dinesh Kumar Srirama S. Venkataraman Ashutosh K. Tewari
ppnlink	1747627801
callnumber-subject	RC - Internal Medicine
mediatype_str_mv	c
isOA_txt	true
hochschulschrift_bool	false
callnumber-a	RC870-923
up_date	2024-07-04T01:19:28.923Z
_version_	1803609407672549376
fullrecord_marcxml	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ057352275</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308211421.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2021 xx \|\|\|\|\|o 00\| \|\|eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ057352275</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ0a209954e0004e55a810d1ab4bfb9ae5</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC870-923</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Jordan Nasri</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Office-Based, Point-of-Care, Low-Field MRI System to Guide Prostate Interventions: Recent Developments</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Abstract Prostate cancer (PCa) is the second most frequently diagnosed cancer in males; early-stage PCa is asymptomatic, and PCa has an indolent course. The current standard of care of systematic transrectal biopsy (SBx) is preferred by urologists because of its ease of use and portability, despite its shortcomings in cancer detection rate. The advent of multi-parametric MRI (mpMRI)-enabled PIRADS protocol for lesion diagnosis and characterisation has helped minimise unnecessary biopsies, supporting the active surveillance protocol of patients with low-risk PCa. The use of annotated pre-procedure MRI fused with real-time ultrasound (US) to guide biopsies has been gaining traction in clinical use, but the challenges in registration of two different modalities, gland deformation due to the probe, and significant learning curve associated with fusion have resulted in slower than expected adoption in routine clinical practice. Moreover, the fusion biopsy has only marginally improved cancer detection rate, with a complex workflow. Higher infection rate with transrectal prostate interventions has resulted in an increased use of the transperineal approach to guide biopsies and therapies. There has been significant progress made in the development of point-of-care, portable MRI systems for specific use. In this report, the authors discuss the recent developments in office-based prostate interventions that have occurred with the arrival of low-field MRI systems. The smaller footprint of the low-field system avoids the high costs associated with the installation and management of regular MRI. Additionally, the availability of transperineal MRI visible grid makes the targeting and guidance processes relatively easier with a less-steep learning curve. Since the system uses pre-plan high-field MRI acquired in the same transverse orientation as the low-field MRI, registration errors are smaller than the MRI–US registration. The use of MRI to target lesions has reduced the number of cores sampled, benefiting the patient with early clinical study showing significantly higher cancer detection rate than SBx.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">low-field mri</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">multi-parametric mri (mpmri)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">portable mri</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">prostate cancer (pca)</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">systematic transrectal biopsy (sbx)</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the genitourinary system. Urology</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Vinayak G. Wagaskar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Sneha Parekha</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">John D. Adams, Jr</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Dinesh Kumar</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Srirama S. Venkataraman</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ashutosh K. Tewari</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">European Medical Journal Urology</subfield><subfield code="d">European Medical Journal, 2015</subfield><subfield code="g">9(2021), 1, Seite 83-90</subfield><subfield code="w">(DE-627)1747627801</subfield><subfield code="x">20534213</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:9</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:1</subfield><subfield code="g">pages:83-90</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/0a209954e0004e55a810d1ab4bfb9ae5</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.emjreviews.com/urology/article/office-based-point-of-care-low-field-mri-system-to-guide-prostate-interventions-recent-developments-j180121/</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2053-4213</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">9</subfield><subfield code="j">2021</subfield><subfield code="e">1</subfield><subfield code="h">83-90</subfield></datafield></record></collection>
score	7.399905

Nicht das Richtige dabei?

Schreiben Sie uns!

Office-Based, Point-of-Care, Low-Field MRI System to Guide Prostate Interventions: Recent Developments

Nicht das Richtige dabei?

Zugang & Verfügbarkeit

Vorhandene Bände

Nicht das Richtige dabei?